1-5 of 5
Zoltán Gasztonyi
Close
Sort by
Journal Articles

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Clinical Trials & Observations
Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P. Skarbnik, Amanda F. Cashen, David T. Weaver, Virginia M. Kelly, Barry Turnbull, Stephan Stilgenbauer
Journal: Blood
Blood (2018) 132 (23): 2446–2455.
https://doi.org/10.1182/blood-2018-05-850461
Published: 2018
Includes: Supplemental data
Journal Articles

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Ian W. Flinn, MD PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Zoltán Gasztonyi, MD, Matthew S. Davids, MD, Klaus Geissler, MD, Jose J. Rifon Roca, MD, Leanne Berkhan, ADHB, Fritz Offner, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Julio Delgado, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3146.
https://doi.org/10.1182/blood-2018-99-120027
Published: 2018
Journal Articles

Results from the Phase 3 DUO TM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ian W. Flinn, MD PhD, Peter Hillmen, MBChB, PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Árpád Illés, MD PhD, Gabriel Etienne, MD PhD, Julio Delgado, MD, Bryone Jean Kuss, PhDBMBS,FRCPA,FRACP, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Zoltán Gasztonyi, MD, Fritz Offner, MD, Scott D Lunin, MD, Francesco Bosch, MD, Matthew S. Davids, MD MMSc, Nicole Lamanna, MD, Ulrich Jaeger, MD, Paolo Ghia, Florence Cymbalista, MD, Craig A. Portell, MD, Alan P Skarbnik, MD, Amanda Cashen, MD, Virginia Kelly, MD, Barry Turnbull, PhD, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 493.
https://doi.org/10.1182/blood.V130.Suppl_1.493.493
Published: 2017
Journal Articles

Immunochemotherapy As Induction (R-CHOP and R-HyperC-VAD/R-MA) in Mantle Cell Lymphoma, a Hungarian Multicenter Open Label Phase II Study (Rituximab [MabThera®] in Mantle Cell Lymphoma, REMENY)

Miklos Udvardy, MD, PhD, Andras Rosta, MD, PhD, Zoltan Gasztonyi, MD, Zita Borbenyi, MD, PhD, Gaspar Radvanyi, MD, Miklos Egyed, MD, PhD, Beata Gasztonyi, MD, PhD, Hajna Losonczy, MD, PhD, Andras Matolcsy, MD, PhD, Agnes H. Andrasfalvy, MD, Tamas J. Schneider, MD
Journal: Blood
Blood (2012) 120 (21): 4889.
https://doi.org/10.1182/blood.V120.21.4889.4889
Published: 2012
Journal Articles

Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura.

Heinz Leibl, PhD, Gyula Varga, MD, Zuzana Volkova, MD, Zoltan Gasztonyi, MD, Antonin Hlusi, MD, Jiri Mayer, MD, Krzysztof Chojnowski, MD, Hans-Heinrich Wolf, MD, Marlies Sharkhawy, MA, Borislava G. Pavlova, PhD, Karl Birthistle, MD, Werner Engl, PhD, Simone Walter, MS, Hartmut J. Ehrlich, MD
Journal: Blood
Blood (2005) 106 (11): 3984.
https://doi.org/10.1182/blood.V106.11.3984.3984
Published: 2005